The FDA has accepted for priority review the biologics license application for odronextamab to treat adults with relapsed/refractory FL or DLBCL whose disease has progressed after at least 2 prior systemic therapies.
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
The FDA has approved Lunsumio (mosunetuzumab-axgb) to treat adults with relapsed/refractory follicular lymphoma after 2 or more lines of systemic therapy.
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
Mosunetuzumab produced an objective response rate of 80%.
Bone marrow biopsies “add little value” to response assessment in patients with follicular lymphoma, according to researchers.
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
